Catabasis Pharmaceuticals, Inc. provided financial guidance for 2020. The company expected quarterly net losses to be higher than Fourth Quarter 2019. The company anticipated net losses to increase over the course of 2020 due to the ongoing Phase III PolarisDMD trial, the increasing number of patients in the GalaxyDMD trial and additional activities to support a potential NDA submission and commercial preparations.